The increasing prevalence of diabetes worldwide has led to a rise in diabetic wounds, such as diabetic foot ulcers, which are challenging to treat and can result in amputation.
Verona Ohtuvayre set to transform US COPD exacerbator market
The FDA has approved Verona Pharma’s first-in-class dual phosphodiesterase 3/4 inhibitor, Ohtuvayre (ensifentrine), for the US market. The asset is tailored towards patients with moderate
June 27, 2024